vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and NOODLES & Co (NDLS). Click either name above to swap in a different company.

NOODLES & Co is the larger business by last-quarter revenue ($122.1M vs $85.1M, roughly 1.4× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -7.5%, a 30.3% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -4.1%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-2.8M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -1.2%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

Noodles & Company is an American fast-casual restaurant that offers international and American noodle dishes in addition to soups and salads. Noodles & Company was founded in 1995 by Aaron Kennedy and is headquartered in Broomfield, Colorado. The company went public in 2013 and recorded a $457 million revenue in 2017. In mid-2022, there were 458 Noodles & Company locations across 31 states.

FDMT vs NDLS — Head-to-Head

Bigger by revenue
NDLS
NDLS
1.4× larger
NDLS
$122.1M
$85.1M
FDMT
Growing faster (revenue YoY)
FDMT
FDMT
+8508904.1% gap
FDMT
8508900.0%
-4.1%
NDLS
Higher net margin
FDMT
FDMT
30.3% more per $
FDMT
22.8%
-7.5%
NDLS
More free cash flow
FDMT
FDMT
$31.3M more FCF
FDMT
$28.5M
$-2.8M
NDLS
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-1.2%
NDLS

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FDMT
FDMT
NDLS
NDLS
Revenue
$85.1M
$122.1M
Net Profit
$19.4M
$-9.2M
Gross Margin
Operating Margin
17.3%
-5.2%
Net Margin
22.8%
-7.5%
Revenue YoY
8508900.0%
-4.1%
Net Profit YoY
139.1%
32.8%
EPS (diluted)
$0.43
$-0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
NDLS
NDLS
Q4 25
$85.1M
Q3 25
$90.0K
$122.1M
Q2 25
$15.0K
$123.8M
Q1 25
$14.0K
Q4 24
$1.0K
$122.8M
Q3 24
$3.0K
$127.4M
Q2 24
$5.0K
$121.4M
Q1 24
$28.0K
$124.3M
Net Profit
FDMT
FDMT
NDLS
NDLS
Q4 25
$19.4M
Q3 25
$-56.9M
$-9.2M
Q2 25
$-54.7M
$-9.1M
Q1 25
$-48.0M
Q4 24
$-6.8M
Q3 24
$-43.8M
$-13.6M
Q2 24
$-35.0M
$-6.1M
Q1 24
$-32.4M
$-6.1M
Operating Margin
FDMT
FDMT
NDLS
NDLS
Q4 25
17.3%
Q3 25
-67983.3%
-5.2%
Q2 25
-396373.3%
-5.2%
Q1 25
-383007.1%
Q4 24
-3.9%
Q3 24
-1704400.0%
-9.0%
Q2 24
-849120.0%
-3.4%
Q1 24
-136200.0%
-3.7%
Net Margin
FDMT
FDMT
NDLS
NDLS
Q4 25
22.8%
Q3 25
-63195.6%
-7.5%
Q2 25
-364386.7%
-7.3%
Q1 25
-342657.1%
Q4 24
-5.5%
Q3 24
-1461433.3%
-10.7%
Q2 24
-699060.0%
-5.1%
Q1 24
-115717.9%
-4.9%
EPS (diluted)
FDMT
FDMT
NDLS
NDLS
Q4 25
$0.43
Q3 25
$-1.01
$-0.20
Q2 25
$-0.98
$-0.20
Q1 25
$-0.86
Q4 24
$-0.15
Q3 24
$-0.79
$-0.30
Q2 24
$-0.63
$-0.14
Q1 24
$-0.66
$-1.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
NDLS
NDLS
Cash + ST InvestmentsLiquidity on hand
$402.7M
$4.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$505.7M
$-38.9M
Total Assets
$566.7M
$280.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
NDLS
NDLS
Q4 25
$402.7M
Q3 25
$305.1M
$4.7M
Q2 25
$293.2M
$1.4M
Q1 25
$321.4M
Q4 24
$424.9M
$3.3M
Q3 24
$501.9M
$1.8M
Q2 24
$541.9M
$1.3M
Q1 24
$525.9M
$3.0M
Stockholders' Equity
FDMT
FDMT
NDLS
NDLS
Q4 25
$505.7M
Q3 25
$369.0M
$-38.9M
Q2 25
$420.9M
$-13.9M
Q1 25
$469.7M
Q4 24
$510.6M
$3.7M
Q3 24
$552.9M
$9.6M
Q2 24
$588.3M
$21.9M
Q1 24
$600.6M
$27.2M
Total Assets
FDMT
FDMT
NDLS
NDLS
Q4 25
$566.7M
Q3 25
$424.0M
$280.6M
Q2 25
$473.6M
$319.4M
Q1 25
$515.7M
Q4 24
$560.4M
$340.5M
Q3 24
$604.0M
$346.3M
Q2 24
$620.1M
$360.4M
Q1 24
$629.9M
$368.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
NDLS
NDLS
Operating Cash FlowLast quarter
$28.6M
$4.3M
Free Cash FlowOCF − Capex
$28.5M
$-2.8M
FCF MarginFCF / Revenue
33.5%
-2.3%
Capex IntensityCapex / Revenue
0.1%
5.8%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M
$-7.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
NDLS
NDLS
Q4 25
$28.6M
Q3 25
$-46.5M
$4.3M
Q2 25
$-43.4M
$4.0M
Q1 25
$-47.8M
Q4 24
$-134.6M
$5.8M
Q3 24
$-29.4M
$4.7M
Q2 24
$-30.2M
$7.0M
Q1 24
$-29.1M
$164.0K
Free Cash Flow
FDMT
FDMT
NDLS
NDLS
Q4 25
$28.5M
Q3 25
$-46.6M
$-2.8M
Q2 25
$-43.4M
$1.1M
Q1 25
$-48.4M
Q4 24
$-138.4M
$-1.3M
Q3 24
$-31.2M
$-4.5M
Q2 24
$-30.6M
$-1.6M
Q1 24
$-29.8M
$-15.2M
FCF Margin
FDMT
FDMT
NDLS
NDLS
Q4 25
33.5%
Q3 25
-51765.6%
-2.3%
Q2 25
-289620.0%
0.9%
Q1 25
-345635.7%
Q4 24
-13837100.0%
-1.1%
Q3 24
-1038966.7%
-3.5%
Q2 24
-611840.0%
-1.4%
Q1 24
-106421.4%
-12.2%
Capex Intensity
FDMT
FDMT
NDLS
NDLS
Q4 25
0.1%
Q3 25
101.1%
5.8%
Q2 25
440.0%
2.4%
Q1 25
4507.1%
Q4 24
378600.0%
5.8%
Q3 24
59266.7%
7.2%
Q2 24
6980.0%
7.1%
Q1 24
2535.7%
12.3%
Cash Conversion
FDMT
FDMT
NDLS
NDLS
Q4 25
1.47×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FDMT
FDMT

Segment breakdown not available.

NDLS
NDLS

Food And Beverage$119.6M98%
Franchise$2.5M2%

Related Comparisons